The Expanding Landscape: Promising Novel Agents in Clinical Trials
To continue, select another chapter from the Chapter List
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
As the treatment landscape for both newly diagnosed and relapsed/refractory AML continues to expand, clinicians must have a practical, working knowledge of the efficacy and safety data of recently approved therapies beyond FLT3 inhibitors as well as novel agents in clinical development. In this activity, Dr. Daniel Pollyea describes several of the current and emerging therapies that are being investigated in clinical trials as treatment for AML.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Outline the efficacy and safety data supporting novel agents for AML currently in clinical development
- Describe ongoing trials investigating new combination therapies in patients with AML
The Expanding Landscape: Promising Novel Agents in Clinical Trials – Daniel A. Pollyea, MD
Instructions for Participation and Credit
This activity is eligible for credit through September 28, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Daniel A. Pollyea, MD
Clinical Director of Leukemia Services
Associate Professor of Medicine
Division of Hematology
University of Colorado
Dr. Daniel Pollyea completed his medical training at the University of Chicago Pritzker School of Medicine and his residency training in internal medicine at the University of Chicago Hospitals. He served as Chief Medical Resident at Chicago’s Cook County Hospital and then went to Stanford University for his fellowship training in hematology and oncology, where he also earned a master’s degree in epidemiology. He is now an Associate Professor of Medicine at the University of Colorado in the Division of Hematology, where he also serves as the Clinical Director of Leukemia Services.
Dr. Pollyea’s research interests involve understanding the nature of leukemia stem cells, and finding ways to target them in clinical trials with novel therapies. He serves as principal investigator of multiple clinical trials, has received grant funding from the Leukemia and Lymphoma Society, and has published more than 60 peer-reviewed journal articles.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-032-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Daniel Pollyea has received honoraria as a consultant from AbbVie Inc., Agios, argenx, Astellas Pharma US, Inc., Celgene Corporation, Celyad, Gilead, and Pfizer Inc. He has received grant support related to research activities from AbbVie Inc. and Pfizer Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.